Skip to content
Screener

Enovis ENOV Surgical — Net Sales

Other product segments

Bracing and Support
$127.61M+5.6%
Other Prevention and Recovery
$59.64M-15.8%

Similar metrics at other companies

Edwards Lifesciences logo
EWSurgical — Net Sales
$284.1M—
MiMedx Group logo
MDXGSurgical — Net Sales
$39.3M+15.1%
The Cooper Companies, Inc. logo
COOOffice and surgical — Net Sales
$214.2M+4.1%
Medtronic logo
MDTMedical Surgical — Net Sales
$2.39B+8.0%
AVN
AVNSSurgical pain and recovery — Net Sales
$21.8M-11.0%
Medline, Inc. logo
MDLNSurgical Solutions — Net Sales
$1.64B+8.7%

Other financials

Income statement

See full
Revenue$582.8M+3.2%
Gross profit$359.2M+7.3%
Operating income$17.4M+204%
Net income-$1.2M+96.8%
EPS (diluted)-$0.02+96.9%

Balance sheet

See full
Cash & equivalents$12.6M-71.5%
Total debt$1.3B-6.4%
Total equity$1.5B-42.7%
Total assets$3.8B-25.0%

Cash flow

See full
Operating cash flow$75.0M+57.1%
CapEx$43.9M-1.1%
Free cash flow$31.1M—

Valuation

See full
Market cap$1.52B+3.1%
Enterprise value$2.81B-0.4%
P/S0.7×0.0×

Profitability

See full
Gross margin61.1%+3.5pp
Operating margin-45.1%+19.4pp
Net margin-48%+17.7pp
FCF margin-3.1%-1.1pp

Returns & leverage

See full
Return on equity-54.3%+672pp
Debt / equity0.9×+0.3×
Current ratio2×-0.3×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Enovis’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:45 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001420800-26-000035
Line itemThree Months Ended / July 3, 2026Three Months Ended / July 4, 2025Six Months Ended / July 3, 2026Six Months Ended / July 4, 2025
U.S. Other P&R (1)59,63770,823115,499137,445
International P&R101,00198,897202,274189,773
Total Prevention & Recovery288,248290,570560,266563,154
Reconstructive:
U.S. Recon137,829129,493287,037267,370
International Recon156,705144,482324,630292,855
Total Reconstructive294,534273,975611,667560,225
Total$582,782$564,545$1,171,933$1,123,379

Item 1. Financial Statements

FAQ

What is Enovis's surgical — net sales?
Enovis (ENOV) reported surgical — net sales of $294.53M in Q2 2026.
How has Enovis's surgical — net sales changed year-over-year?
Enovis's surgical — net sales increased by 7.5% year-over-year, from $273.98M to $294.53M.
What is the long-term trend for Enovis's surgical — net sales?
Over 4 years (2021 to 2025), Enovis's surgical — net sales has grown at a 29.1% compound annual growth rate (CAGR), from $400.16M to $1.11B.
What does surgical — net sales mean?
This metric represents the total revenue generated from the sale of products and services within the company's surgical division after deducting returns, allowances, and discounts. It serves as a primary indicator of market demand and the commercial success of the company's reconstructive and surgical medical device portfolio. Tracking this figure allows investors to assess the growth trajectory and competitive positioning of the surgical business unit relative to broader market trends.

Ask your AI about Enovis's surgical — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude